[go: up one dir, main page]

AR116887A2 - Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares - Google Patents

Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares

Info

Publication number
AR116887A2
AR116887A2 ARP190103126A ARP190103126A AR116887A2 AR 116887 A2 AR116887 A2 AR 116887A2 AR P190103126 A ARP190103126 A AR P190103126A AR P190103126 A ARP190103126 A AR P190103126A AR 116887 A2 AR116887 A2 AR 116887A2
Authority
AR
Argentina
Prior art keywords
progression
kit
delay
decrease
pulmonary exacerbations
Prior art date
Application number
ARP190103126A
Other languages
English (en)
Inventor
William Barnett
Les Garlinghouse
Royce Waltrip
Mark Forshag
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of AR116887A2 publication Critical patent/AR116887A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares que comprende el inhibidor de a1-proteinasa (A1PI) en un recipiente listo para utilizar.
ARP190103126A 2011-12-30 2019-10-29 Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares AR116887A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
AR116887A2 true AR116887A2 (es) 2021-06-23

Family

ID=47470050

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120104411A AR088971A1 (es) 2011-12-30 2012-11-23 INHIBIDOR DE a₁-PROTEINASA PARA DEMORAR EL COMIENZO O PROGRESION DE EXACERBACIONES PULMONARES
ARP190103126A AR116887A2 (es) 2011-12-30 2019-10-29 Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120104411A AR088971A1 (es) 2011-12-30 2012-11-23 INHIBIDOR DE a₁-PROTEINASA PARA DEMORAR EL COMIENZO O PROGRESION DE EXACERBACIONES PULMONARES

Country Status (18)

Country Link
US (1) US9421248B2 (es)
EP (1) EP2758065B1 (es)
JP (4) JP2015504051A (es)
KR (1) KR20140108516A (es)
CN (2) CN103889436A (es)
AR (2) AR088971A1 (es)
AU (1) AU2012337241B2 (es)
BR (1) BR112014007127A2 (es)
CA (1) CA2844878C (es)
CL (1) CL2014000722A1 (es)
ES (1) ES2887358T3 (es)
IL (1) IL231109B (es)
MX (1) MX351189B (es)
MY (1) MY166314A (es)
RU (1) RU2635482C2 (es)
SG (2) SG10201610913PA (es)
UY (1) UY34465A (es)
WO (1) WO2013098672A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030254A2 (en) * 2013-08-05 2016-06-15 Gerard Voerman Novel means to decrease the negative effects of smoking
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
ES2970115T3 (es) * 2015-02-05 2024-05-27 Canem Holdings Llc Composiciones para el tratamiento de la granulomatosis con poliangeítis
WO2018154568A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
WO2020014326A1 (en) * 2018-07-10 2020-01-16 Ciancone Christopher V Breath measurement device
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
AU2020340281A1 (en) * 2019-08-23 2022-04-07 Ph Pharma Co., Ltd. Use of a neutrophil elastase inhibitor in lung disease
KR20230005965A (ko) * 2020-05-01 2023-01-10 아틀라스 바이오테크놀로지 에스.에이. 바이러스 감염 관련 질환 또는 증후군의 치료 및/또는 예방

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
WO1986000337A1 (fr) 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
NZ285664A (en) 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
EP1736483A3 (en) 1995-09-07 2008-07-30 Pharming Intellectual Property BV Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
GEP20043260B (en) 1998-03-16 2004-06-25 Nectar Therapeutics Aerosolized Active Agent Delivery and Device for Realization Thereof
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
JP4426179B2 (ja) 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
US7879800B2 (en) 2003-09-22 2011-02-01 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
WO2005048985A2 (en) 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
CA2559062A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
DK1981572T3 (da) * 2006-02-09 2013-03-04 Pari Pharma Gmbh Pulmonal afgivelse af alfa-1-proteinaseinhibitor
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
WO2010009388A1 (en) 2008-07-18 2010-01-21 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
AU2010315325B2 (en) * 2009-11-03 2014-11-27 Grifols Therapeutics Inc. Composition, method, and kit for alpha-1 proteinase inhibitor

Also Published As

Publication number Publication date
WO2013098672A2 (en) 2013-07-04
MY166314A (en) 2018-06-25
CN107596359A (zh) 2018-01-19
US9421248B2 (en) 2016-08-23
AR088971A1 (es) 2014-07-23
UY34465A (es) 2013-07-31
EP2758065A2 (en) 2014-07-30
EP2758065B1 (en) 2021-06-23
WO2013098672A3 (en) 2013-10-24
KR20140108516A (ko) 2014-09-11
SG10201610913PA (en) 2017-02-27
RU2635482C2 (ru) 2017-11-13
AU2012337241B2 (en) 2016-10-13
JP2015504051A (ja) 2015-02-05
AU2012337241A1 (en) 2013-07-18
BR112014007127A2 (pt) 2017-04-04
IL231109B (en) 2018-02-28
ES2887358T3 (es) 2021-12-22
MX351189B (es) 2017-10-04
SG2014012066A (en) 2014-09-26
CL2014000722A1 (es) 2014-10-10
CA2844878C (en) 2017-11-28
NZ621596A (en) 2016-08-26
CA2844878A1 (en) 2013-07-04
IL231109A0 (en) 2014-04-30
HK1198918A1 (en) 2015-06-19
JP2017039745A (ja) 2017-02-23
JP2018104439A (ja) 2018-07-05
MX2014001764A (es) 2014-04-30
US20150011460A1 (en) 2015-01-08
CN103889436A (zh) 2014-06-25
RU2014106758A (ru) 2015-08-27
JP2019135243A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
AR116887A2 (es) Kit para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares
CY2022018I2 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
IL227399A0 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
BR112013028235A2 (pt) refrigerador
CR20140024A (es) Compuestos inhibidores de metaloenzimas
CR20150507A (es) Inhibidores de histona desmetilasas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
PT3628670T (pt) Forma salina de um inibidor de ezh2
DK3196202T3 (da) Heterocyclylaminer som pi3k-inhibitorer
UY33930A (es) Inhibidores novedosos de quinasas
HRP20151310T1 (xx) Spojevi piridazinona i njihova uporaba kao inhibitori daao
MX2020008031A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
BR112013029784A2 (pt) bomba
CO7020915A2 (es) Inhibidores de iap
FR2981739B1 (fr) Compresseur frigorifique
BR112014013218A2 (pt) composição para prolongar a vida útil de produtos frescos
FI20155150L (fi) Koostumus krapulan oireiden ehkäisemiseksi
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CO6801745A2 (es) Composición que comprende diaminooxidasa para la prevención de los sintomas de la resaca
FR3002724B1 (fr) Kit pour la consommation par inhalation
TWD157218S1 (zh) 冰樁
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FB Suspension of granting procedure